Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.80 |
| ▸ | NPC1 | O15118 | 7/20 | 0.80 |
| ▸ | RAB9A | P51151 | 6/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.65 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.65 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.65 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681347 | 0.89 | NPC1 (0.80) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL2982452 | 0.88 | MEN1 (0.77) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL4254970 | 0.86 | RAB9A (0.75) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL667807 | 0.86 | BCAT2 (0.77) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL3089807 | 0.86 | MEN1 (0.75) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL3645013 | 0.86 | MEN1 (0.74) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL10939703 | 0.85 | NPC1 (0.76) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9767723 | 0.85 | NPC1 (0.76) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL611657 | 0.85 | NPC1 (0.76) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL12190100 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067538-B2 | MCP-1 receptor antagonists and methods of use thereof | WARNER-LAMBERT COMPANY, LLC (US) | 2006-06-27 | — | — | US | claimed |
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | BRATTON LARRY D (US) | 2005-08-04 | — | — | US | claimed |
| EP-1539685-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004014847-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-7067538-B2 | MCP-1 receptor antagonists and methods of use thereof | WARNER-LAMBERT COMPANY, LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | BRATTON LARRY D (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1539685-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014847-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | CCR2, CCR1, CCL2 | MEN1 3631/4885KMT2A 3687/4885NPC1 1096/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | MEN1 1233/4885KMT2A 632/4885NPC1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.